Neovascular Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Neovascular Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-04-04Clinical Trial Update: An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study [Phase 3]
This clinical trial update reports the extension study of brolucizumab for neovascular age-related macular degeneration, evaluating efficacy…
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration [Phase 3]
A Phase 3 trial comparing SOK583A1 to Eylea in neovascular age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration [Phase 1, Phase 2]
Phase 1/2 trial update on safety and bioactivity of AXT107 in neovascular age-related macular degeneration; study terminated with posted res…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
An extension study update assessing long-term outcomes from the CLS-AX CLS1002-101 trial in patients with neovascular age-related macular de…
-
CLINICAL_TRIALS trial_result · 2024-02-05Clinical Trial Update: A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial comparing SB15, a proposed aflibercept biosimilar, to Eylea in neovascular age-related macular degeneration has completed with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-01-18Clinical Trial Update: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration [Phase 3]
A Phase 3 trial comparing a 36-week refill regimen of the Port Delivery System with ranibizumab versus aflibercept treat-and-extend in neova…
-
CLINICAL_TRIALS trial_result · 2024-01-09Clinical Trial Update: A Study of EXG102-031 in Participants With wAMD [Phase 1, Phase 2]
A study update for EXG102-031 investigating its safety and efficacy in neovascular age-related macular degeneration across Phase 1 and Phase…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD] [Phase 3]
Phase 3 study comparing ABP 938 to Aflibercept (Eylea) in neovascular (wet) age-related macular degeneration has completed with results post…
-
FDA approval · 2023-10-26FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for VABYSMO (faricimab) by Genentech, expanding its labeling/indication via supplemental approval.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial comparing SCD411 to Eylea in wet/ neovascular age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe [Phase 3]
Phase 3 trial update assessing the safety of the faricimab prefilled syringe in patients with neovascular age-related macular degeneration o…
-
FDA approval · 2023-10-03FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved Biogen's BYOOVIZ (ranibizumab-nuna) via a supplemental application, providing an additional approval for this ranibizumab biosi…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye [Phase 3]
A Phase 3 study evaluating high-dose aflibercept injected into the eye for neovascular age-related macular degeneration has completed, with …
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and tolerability of suprachoroidal CLS-AX injection after anti-VEGF therapy in neovascular age-related mac…
-
FDA approval · 2023-08-18FDA Approved: EYLEA HD — Original Application (Regeneron Pharmaceuticals, Inc)
FDA approved a high-dose formulation of EYLEA (aflibercept) under a new original application for its retinal disease indications.
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration [Phase 2]
Phase 2 clinical trial updating safety, tolerability, and efficacy of aflibercept for neovascular age-related macular degeneration has compl…
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial [Phase 1, Phase 2]
A phase 1/2 trial update reports safety and tolerability findings for RGX-314 gene therapy in neovascular age-related macular degeneration, …
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit [Phase 3]
Phase 3 trial update evaluating the safety of intravitreal SOK583A1 in a vial kit for neovascular age-related macular degeneration has compl…
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD [Phase 3]
A Phase 3 randomized, double-masked trial evaluating KH902 for wet age-related macular degeneration has completed.
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD [Phase 2]
A Phase 2 safety study evaluating Zimura in combination with anti-VEGF therapy for neovascular age-related macular degeneration was terminat…
-
CLINICAL_TRIALS trial_result · 2023-02-22Clinical Trial Update: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections [Phase 4]
Phase 4 trial update on DEXTENZA for pain and inflammation in patients receiving intravitreal anti-VEGF injections; study terminated.
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration [Phase 3]
Phase 3 trial update on aflibercept for neovascular age-related macular degeneration assessing efficacy and safety.
-
FDA approval · 2023-01-27FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for VABYSMO (faricimab) from Genentech, Inc., regarding an updated indication or labeling. This …
-
FDA approval · 2022-12-19FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for BEOVU (brolucizumab) from Novartis Pharmaceuticals Corporation. This action approves an expa…
-
CLINICAL_TRIALS trial_result · 2022-11-18Clinical Trial Update: Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe [Phase 3]
Phase 3 trial assessing safety of intravitreal SOK583A1 in a prefilled syringe for neovascular age-related macular degeneration (nAMD) compl…